DD Stock Analysis: Dupont De Nemours | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 18.745m USD | 12M Return: 50.6% | US26614N2018 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 209M
EPS Trend: -11.9%
Qual. Beats: 2
Rev. Trend: -67.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DuPont de Nemours, Inc. (NYSE: DD) is a global technology-based materials and solutions provider operating across the United States, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa. The company is organized into two reporting segments: Healthcare & Water Technologies and Diversified Industrials, serving end markets that include medical devices, water treatment, construction, automotive, aerospace, printing, and packaging.
The company markets a wide portfolio of well-known specialty brands. Healthcare and water-related offerings include TYVEK-based protective and packaging materials, AMBERLITE ion exchange resins, FILMTEC reverse osmosis and nanofiltration elements, and INGE and ITEGRATEC ultrafiltration modules. Construction-oriented products include TYVEK house wrap, STYROFOAM insulation, and CORIAN solid surface. Industrial offerings include Vespel parts, MOLYKOTE specialty lubricants, BETAFORCE and BETASEAL structural adhesives, and Cyrel flexographic printing plates.
DuPont de Nemours is classified in the GICS Materials sector under the Diversified Chemicals sub-industry, reflecting its broad exposure to specialty chemicals and engineered materials rather than a single end market. The current entity was incorporated in 2015 and adopted the DuPont de Nemours name in June 2019 following the unwinding of the DowDuPont merger, with shares listed on the NYSE under the ticker DD.
- Electronics materials revenue tracks semiconductor cycle recovery
- Construction weakness pressures Tyvek and insulation volumes
- Water technologies grows on industrial and desalination demand
| Net Income: 55.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.74 > 1.0 |
| NWC/Revenue: 34.54% < 20% (prev 16.27%; Δ 18.28% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.27b > Net Income 55.0m |
| Net Debt (1.39b) to EBITDA (1.33b): 1.05 < 3 |
| Current Ratio: 2.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (137.2m) vs 12m ago -1.93% < -2% |
| Gross Margin: 34.39% > 18% (prev 32.96%; Δ 1.43% > 0.5%) |
| Asset Turnover: 28.69% > 50% (prev 33.58%; Δ -4.89% > 0%) |
| Interest Coverage Ratio: 3.22 > 6 (EBIT TTM 777.0m / Interest Expense TTM 241.0m) |
| A: 0.14 (Total Current Assets 4.86b - Total Current Liabilities 2.00b) / Total Assets 21.1b |
| B: -1.16 (Retained Earnings -24.3b / Total Assets 21.1b) |
| C: 0.03 (EBIT TTM 777.0m / Avg Total Assets 28.8b) |
| D: 1.92 (Book Value of Equity 13.8b / Total Liabilities 7.18b) |
| Altman-Z'' = -0.68 = B |
| DSRI: 1.10 (Receivables 1.75b/2.36b, Revenue 8.27b/12.3b) |
| GMI: 0.96 (GM 32.96% / 34.39%) |
| AQI: 0.94 (AQ_t 0.61 / AQ_t-1 0.65) |
| SGI: 0.67 (Revenue 8.27b / 12.3b) |
| TATA: -0.06 (NI 55.0m - CFO 1.27b) / TA 21.1b) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of August 23, 2026, the stock is trading at USD 138.33 with a total of 1,119,063 shares traded. Over the past week, the price has changed by -5.42%, over one month by -0.33%, over three months by -2.21% and over the past year by +50.62%.
Current recommended Stop Loss: 128.00 (which is 7.5% or 2.6 ATR below the current price).
Dupont De Nemours has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy DD.
- StrongBuy: 11
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 170 | 22.9% |
P/E Trailing = 61.4204
P/E Forward = 20.1613
P/S = 2.6825
P/B = 1.4032
P/EG = 1.7173
Revenue TTM = 8.27b USD
EBIT TTM = 777.0m USD
EBITDA TTM = 1.33b USD
Long Term Debt = 3.12b USD (from longTermDebt, last quarter)
Short Term Debt = 60.0m USD (from shortTermDebt, last fiscal year)
Debt = 3.13b USD (from shortLongTermDebtTotal, last quarter) + Leases 9.00m
Net Debt = 1.39b USD (calculated: Debt 3.13b - CCE 1.74b)
Enterprise Value = 20.1b USD (18.7b + Debt 3.13b - CCE 1.74b)
Interest Coverage Ratio = 3.22 (Ebit TTM 777.0m / Interest Expense TTM 241.0m)
EV/FCF = 17.85x (Enterprise Value 20.1b / FCF TTM 1.13b)
FCF Yield = 5.60% (FCF TTM 1.13b / Enterprise Value 20.1b)
FCF Margin = 13.65% (FCF TTM 1.13b / Revenue TTM 8.27b)
Net Margin = 0.67% (Net Income TTM 55.0m / Revenue TTM 8.27b)
Gross Margin = 34.39% ((Revenue TTM 8.27b - Cost of Revenue TTM 5.42b) / Revenue TTM)
Gross Margin QoQ = 35.13% (prev 35.81%)
Tobins Q-Ratio = 0.96 (Enterprise Value 20.1b / Total Assets 21.1b)
Interest Expense / Debt = 7.69% (Interest Expense 241.0m / Debt 3.13b)
Taxrate = 23.59% (167.0m / 708.0m)
NOPAT = 593.7m (EBIT 777.0m * (1 - 23.59%))
Current Ratio = 2.43 (Total Current Assets 4.86b / Total Current Liabilities 2.00b)
Debt / Equity = 0.23 (Debt 3.13b / totalStockholderEquity, last quarter 13.8b)
Debt / EBITDA = 1.05 (Net Debt 1.39b / EBITDA 1.33b)
Debt / FCF = 1.24 (Net Debt 1.39b / FCF TTM 1.13b)
Total Stockholder Equity = 16.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.19% (Net Income 55.0m / Total Assets 21.1b)
RoE = 0.34% (Net Income TTM 55.0m / Total Stockholder Equity 16.2b)
RoCE = 4.03% (EBIT 777.0m / Capital Employed (Equity 16.2b + L.T.Debt 3.12b))
RoIC = 3.17% (NOPAT 593.7m / Invested Capital 18.7b)
WACC = 9.63% (E(18.7b)/V(21.9b) * Re(10.26%) + D(3.13b)/V(21.9b) * Rd(7.69%) * (1-Tc(0.24)))
Discount Rate = 10.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -85.60 | Cagr: -1.34%
[DCF] Terminal Value 68.52% ; FCFF base≈1.21b ; Y1≈1.06b ; Y5≈862.4m
[DCF] Fair Price = 74.25 (EV 11.4b - Net Debt 1.39b = Equity 10.0b / Shares 135.0m; r=9.63% [WACC]; 5y FCF grow -14.67% → 2.50% )
EPS Correlation: -11.93 | EPS CAGR: -1.86% | SUE: 0.92 | # QB: 2
Revenue Correlation: -67.14 | Revenue CAGR: -8.77% | SUE: 0.01 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.90 | Chg30d=-1.73% | Revisions=-40% | Analysts=12
EPS current Year (2026-12-31): EPS=7.26 | Chg30d=+1.40% | Revisions=+35% | GrowthEPS=+44.1% | GrowthRev=+4.6%
EPS next Year (2027-12-31): EPS=7.96 | Chg30d=+0.90% | Revisions=+12% | GrowthEPS=+9.7% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: +5% (up=21, down=19)